Regeneron Pharmaceuticals Stock Probability of Future Stock Price Finishing Over 738.0
| REGN Stock | USD 738.00 6.50 0.87% |
Regeneron |
Regeneron Pharmaceuticals Target Price Odds to finish over 738.0
The tendency of Regeneron Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 738.00 | 90 days | 738.00 | roughly 97.0 |
Based on a normal probability distribution, the odds of Regeneron Pharmaceuticals to move above the current price in 90 days from now is roughly 97.0 (This Regeneron Pharmaceuticals probability density function shows the probability of Regeneron Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Regeneron Pharmaceuticals has a beta of 0.82 indicating as returns on the market go up, Regeneron Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Regeneron Pharmaceuticals will be expected to be much smaller as well. Additionally Regeneron Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Regeneron Pharmaceuticals Price Density |
| Price |
Predictive Modules for Regeneron Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Regeneron Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Regeneron Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Regeneron Pharmaceuticals is not an exception. The market had few large corrections towards the Regeneron Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Regeneron Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Regeneron Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.78 | |
β | Beta against Dow Jones | 0.82 | |
σ | Overall volatility | 142.99 | |
Ir | Information ratio | -0.47 |
Regeneron Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Regeneron Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Regeneron Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Regeneron Pharmaceuticals generated a negative expected return over the last 90 days | |
| Regeneron Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Vyriad signs huge deal with Novartis to develop new cancer treatments |
Regeneron Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Regeneron Stock often depends not only on the future outlook of the current and potential Regeneron Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Regeneron Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 113.7 M | |
| Cash And Short Term Investments | 10.8 B |
Regeneron Pharmaceuticals Technical Analysis
Regeneron Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Regeneron Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Regeneron Pharmaceuticals. In general, you should focus on analyzing Regeneron Stock price patterns and their correlations with different microeconomic environments and drivers.
Regeneron Pharmaceuticals Predictive Forecast Models
Regeneron Pharmaceuticals' time-series forecasting models is one of many Regeneron Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Regeneron Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Regeneron Pharmaceuticals
Checking the ongoing alerts about Regeneron Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Regeneron Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Regeneron Pharmaceuticals generated a negative expected return over the last 90 days | |
| Regeneron Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Vyriad signs huge deal with Novartis to develop new cancer treatments |
Check out Regeneron Pharmaceuticals Backtesting, Regeneron Pharmaceuticals Valuation, Regeneron Pharmaceuticals Correlation, Regeneron Pharmaceuticals Hype Analysis, Regeneron Pharmaceuticals Volatility, Regeneron Pharmaceuticals History as well as Regeneron Pharmaceuticals Performance. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.298 | Earnings Share 40.43 | Revenue Per Share 128.691 | Quarterly Revenue Growth 0.106 | Return On Assets 0.0741 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.